Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 11/2014

01-11-2014 | Review Article

Side Effects of Cytokines Approved for Therapy

Author: Brian A. Baldo

Published in: Drug Safety | Issue 11/2014

Login to get access

Abstract

Cytokines, currently known to be more than 130 in number, are small MW (<30 kDa) key signaling proteins that modulate cellular activities in immunity, infection, inflammation and malignancy. Key to understanding their function is recognition of their pleiotropism and often overlapping and functional redundancies. Classified here into 9 main families, most of the 20 approved cytokine preparations (18 different cytokines; 3 pegylated), all in recombinant human (rh) form, are grouped in the hematopoietic growth factor, interferon, platelet-derived growth factor (PDGF) and transforming growth factor β (TGFβ) families. In the hematopoietin family, approved cytokines are aldesleukin (rhIL-2), oprelvekin (rhIL-11), filgrastim and tbo-filgrastim (rhG-CSF), sargramostim (rhGM-CSF), metreleptin (rh-leptin) and the rh-erythropoietins, epoetin and darbepoietin alfa. Anakinra, a recombinant receptor antagonist for IL-1, is in the IL-1 family; recombinant interferons alfa-1, alfa-2, beta-1 and gamma-1 make up the interferon family; palifermin (rhKGF) and becaplermin (rhPDGF) are in the PDGF family; and rhBMP-2 and rhBMP-7 represent the TGFβ family. The main physicochemical features, FDA-approved indications, modes of action and side effects of these approved cytokines are presented. Underlying each adverse events profile is their pleiotropism, potency and capacity to release other cytokines producing cytokine ‘cocktails’. Side effects, some serious, occur despite cytokines being endogenous proteins, and this therefore demands caution in attempts to introduce individual members into the clinic. This caution is reflected in the relatively small number of cytokines currently approved by regulatory agencies and by the fact that 14 of the FDA-approved preparations carry warnings, with 10 being black box warnings.
Literature
1.
2.
3.
Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7:21–39.PubMed
4.
5.
Baldo BA, Pham NH. Drug allergy. Clinical aspects, diagnosis, mechanisms, structure-activity relationships. New York: Springer; 2013.
6.
Ducancel F, Muller BH. Molecular engineering of antibodies for therapeutic and diagnostic purposes. mAbs 2012;4:445–57.
7.
Kaneko E, Niwa R. Optimizing therapeutic antibody function: progress with Fc domain engineering. BioDrugs. 2011;25:1–11.PubMed
8.
9.
Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14:529–37.PubMed
10.
Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325–38.PubMed
11.
12.
Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013;63:249–79.PubMed
13.
Baldo BA, Pagani M. Adverse events to non-targeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses. Immunol Allergy Clin N Am. 2014;34:565–96.
14.
Vazquez-Lombardi R, Roome B, Christ D. Molecular engineering of therapeutic cytokines. Antibodies. 2013;2:426–51.
15.
16.
Wurm F, Bernard A. Large-scale transient expression in mammalian cells for recombinant protein production. Curr Opin Biotechnol. 1999;10:156–9.PubMed
17.
Brannigan JA, Wilkinson AJ. Protein engineering 20 years on. Nature Rev Mol Cell Biol. 2002;3:964–70.
18.
Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Brit J Cancer. 2001;84(Suppl. 1):3–10.PubMedPubMedCentral
19.
Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin Immunol. 2003;111:S460–75.PubMed
20.
Steinke JW, Borish L. 3. Cytokines and chemokines. J Allergy Clin Immunol. 2006;117:S441–5.PubMed
21.
Tayal V, Kalra BS. Cytokines and anti-cytokines as therapeutics—an update. Eur J Pharmacol. 2008;579:1–12.PubMed
22.
23.
Tato CM, Cua DJ. Snapshot: Cytokines I. Cell. 2008;132:324-e1.
24.
Tato CM, Cua DJ. Snapshot: Cytokines II. Cell. 2008;132:500-e1.
25.
Tato CM, Cua DJ. Snapshot: Cytokines III. Cell. 2008;132:900-e1.
26.
Tato CM, Cua DJ. Snapshot: Cytokines IV. Cell. 2008;132:1062-e1.
27.
28.
Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967–72.PubMed
29.
30.
31.
Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:s237–44.PubMed
32.
Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry. 2005;66:1050–7.PubMed
33.
Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol. 2010;24:183–92.PubMed
34.
Poreaux C, Bronowicki J-P, Debouverie M, et al. Managing generalized interferon-induced eruptions and the effectiveness of desensitization. Clin Exp Allergy. 2014;44:756–64.PubMed
35.
36.
Kraus MR, Schäfer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry. 2003;64:708–14.PubMed
37.
Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27–36.PubMed
38.
Kraus MR, Schäfer A, Csef H, et al. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol. 2005;11:1769–74.PubMed
39.
40.
41.
42.
Rudick RA, Ransohoff RM, Lee JC, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology. 1998;50:1294–300.PubMed
43.
Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology. 1999;53:1622–7.PubMed
44.
Markowitz CE. Interferon-beta. Mechanism of action and dosing issues. Neurology. 2007;68(suppl 4):S8–11.PubMed
45.
Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs. 2011;25:491–502.PubMed
46.
47.
48.
Ealick SE, Cook WJ, Vijay-Kumar S, et al. Three-dimensional structure of recombinant human interferon-gamma. Science. 1991;252:698–702.PubMed
49.
Thiel DJ, le Du MH, Walter RL, et al. Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex. Structure. 2000;8:927–36.PubMed
50.
Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163–89.PubMed
51.
Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41–101.PubMed
52.
53.
54.
Bonilla MA, Dale D, Zeidler C, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol. 1994;88:723–30.PubMed
55.
Cottle TE, Fier CJ, Donadieu J, et al. Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. Semin Hematol. 2002;39:134–40.PubMed
56.
Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004;10:1235–44.PubMed
57.
58.
59.
60.
del Giglio A, Eniu A, Ganea-Motan D, et al. XM02 is superior to placebo and equivalent to Neupogen® in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle I in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer. 2008;8:332–8.PubMedPubMedCentral
61.
62.
63.
Hercus TR, Broughton SE, Ekert PG, et al. The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors. 2012;30:63–75.PubMed
64.
65.
Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1–20.PubMedPubMedCentral
66.
Vredenburgh JJ, Hussein A, Fisher D, et al. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cells support in patients with breast cancer. Biol Blood Marrow Transplant. 1998;4:134–41.PubMed
67.
Kaye JA. FDA licensure of Neumega® to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells. 1998;16(suppl 2):207–23.PubMed
68.
69.
Steed DL, the Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg. 1995;21:71–81.PubMed
70.
Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care. 1998;21:822–7.PubMed
71.
Barman Balfour JA, Noble S. Becaplermin. BioDrugs. 1999;11:359–64.
72.
Rubin JS, Osada H, Finch PW. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Nat Acad Sci. 1989;86:802–6.PubMedPubMedCentral
73.
74.
Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Annals Oncol. 2006;18:817–26.
75.
Spielberger R, Stiff P, Bensinger W. Palifermin for oral mucositis after intensive therapy for hematologic malignancies. N Engl J Med. 2004;351:2590–8.PubMed
76.
77.
78.
Ravaud A, Negrier S, Lakdja F, et al. Adverse effects of interleukin 2 [Article in French]. Bull Cancer. 1991;78:989–1005.PubMed
79.
80.
Geertsen PF, Gore ME, Negrier S, et al. Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer. 2004;90:1156–62.PubMedPubMedCentral
81.
Spoerl D, Bircher AJ. Drugs that act on the immune system: cytokines and monoclonal antibodies. In: Aronson JK, editor. Side effects of drugs annual 33. Amsterdam: Elsevier; 2011. p. 777–8.
82.
83.
Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis. Arthritis Rheum. 2003;48:927–34.PubMed
84.
Swart JF, Barug D, Möhlmann M, et al. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Therapy. 2010;10:1743–52.
85.
86.
Elliott SG, Foote M, Molineux G, editors. Erythropoietins, erythropoietic factors, and erythropoiesis: Molecular, cellular, preclinical, and clinical biology. 2nd ed. Basel: Birkhauser Verlag; 2009.
87.
Cheung JY, Miller BA. Molecular mechanisms of erythropoietin signaling. Nephron. 2001;87:215–22.PubMed
88.
Smith KJ, Bleyer AJ, Little WC, et al. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003;59:538–48.PubMed
89.
McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48:1754–62.PubMedPubMedCentral
90.
McCullough PA, Barnhart HX, Inrig JK, et al. Cardiovascular toxicity of epoetin alfa in patients with chronic kidney disease. Am J Nephrol. 2013;37:549–58.PubMed
91.
92.
Canon J-L, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoietin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst. 2006;98:273–84.PubMed
93.
Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoietin alfa on exercize tolerance in anemic patients with symptomatic chronic heart failure. J Am Coll Cardiol. 2007;49:753–62.PubMed
94.
95.
Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22:233–41.PubMed
96.
Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). J Tissue Eng Regen Med. 2008;2:1–13.PubMed
97.
Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011;11:471–91.PubMed
98.
Woo EJ. Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience Database. Spine J. 2012;12:894–9.PubMed
99.
Tannoury CA, An HS. Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J. 2014;14:552–9.PubMed
100.
Baldo BA. Drugs that act on the immune system: cytokines and monoclonal antibodies. In: Aronson JK, editor. Side effects of drugs annual 36. Amsterdam: Elsevier; 2015 (In press).
101.
102.
Marcias-Silva M, Hoodless PA, Tang SJ, et al. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J Biol Chem. 1998;273:25628–36.
103.
104.
105.
106.
107.
Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537–56.PubMed
108.
Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity. 2009;17:1736–43.PubMedPubMedCentral
109.
Margetic S, Gazzola C, Pegg GG, et al. Leptin: a review of its peripheral actions and interactions. Int J Obesity. 2002;26:1407–33.
110.
Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24:38–47.PubMed
111.
Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283–91.PubMed
112.
Dusheiko G (1997) Side effects of alpha interferon in chronic hepatitis C. Hepatology 26(Issue 3):112S–121S).
113.
Fontaine H, Pol S. Side effects of interferon-α in treating hepatitis C virus infection. Transpl Proc. 2001;33:2327–9.
114.
115.
Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10:1451–8.PubMed
116.
Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Discord. 2002;72:237–41.
117.
Dieperink E, Ho SB, Thuras P, et al. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 2003;44:104–12.PubMed
118.
Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942–7.PubMed
119.
Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol. 2002;22:86–90.PubMed
120.
Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther. 2002;16:1091–9.PubMed
121.
Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54:906–14.PubMed
122.
Schaefer M, Schwaiger M, Pich M, et al. Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry. 2003;36(Suppl 3):S203–6.PubMed
123.
Schaefer M, Horn M, Schmidt F, et al. Correlation betweensICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon alpha. Brain Behav Immun. 2004;18:555–62.PubMed
124.
Raison CL, Demetrashvili M, Capuron L, et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19:105–23.PubMedPubMedCentral
125.
Tóthová E, Kafková A, Stecová N, et al. Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia. Neoplasma. 2002;49:91–4.PubMed
126.
Yagyu H, Okada K, Sato S, et al. Pegylated interferon-alpha2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus. Diabetes Res Clin Pract. 2012;95:e52–4.PubMed
127.
Pinto JL, Pinto ME. Tiroiditis autoinmune inducida por interferón en pacientes con infección por virus de la hepatitis C [Interferon-induced autoimmune thyroiditis in a patient with hepatitis C virus infection.]. Rev Peru Med Exp Salud Publica. 2011;28:382–4.PubMed
128.
Yılmaz S, Cimen KA. Pegylated interferon alfa-2b induced lupus in a patient with chronic hepatitis B virus infection: case report. Clin Rheumatol. 2009;28:1241–3.PubMed
129.
Ho V, Mclean A, Shaughan T. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J Clin Rheumatol. 2008;14:166–8.PubMed
130.
Abbott IJ, Chang CC, Skinner MJ, et al. Development and management of systemic lupus erythematosus in an HIV-infected man with hepatitis C and B co-infection following interferon therapy: a case report. J Med Case Rep. 2009;3:7289.PubMedPubMedCentral
131.
Agarwal SK, Lal C, Zaidi SH. Lupus activation with cerebritis following pegylated interferon in a hemodialysis patient. Nat Rev Nephrol. 2009;5:599–603.PubMed
132.
Popescu C, Arama V, Gliga S. Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis—case report. BMC Gastroenterol. 2011;11:30.PubMedPubMedCentral
133.
Kuwara A, Ohashi M, Sugiyama M, et al. A case of reversible dilated cardiomyopathy after alpha-interferon therapy in a patient with renal cell carcinoma. Am J Med Sci. 2002;324:331–4.
134.
Gupta SK, Glue P, Jacobs S, et al. Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects. Br j Clin Pharmacol. 2003;56:131–4.PubMedPubMedCentral
135.
Gressens B, Gohy P. Pericarditis due to interferon-alpha therapy during treatment for chronic hepatitis C. Acta Gastroenterol Belg. 2004;67:301–2.PubMed
136.
Rauw J, Ahmed S, Petrella T. Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma. Med Oncol. 2012;29:1304–7.PubMed
137.
Sakabe M, Yoshioka R, Fujiki A. Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. J Cardiol Cases. 2013;8:173–5.
138.
Wang BY, Chang HH, Chen IM, et al. Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient. Ann Thorac Surg. 2010;89:1645–7.PubMed
139.
Kumar KS, Russo MW, Borczuk AC, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol. 2002;97:2432–40.PubMed
140.
Midturi J, Sierra-Hoffman M, Hurley D, et al. Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature. Clin Infect Dis. 2004;39:1724–9.PubMed
141.
Kaneko R, Ogawa M, Iwata T, et al. Ursodeoxycholic acid exacerbates peginterferon-induced interstitial pneumonia in a patient with hepatitis C. Clin J Gastroenterol. 2009;2(4):296–9. doi:10.​1007/​s12328-009-0075-y.
142.
Ando S, Kawai K, Kuriyagawa K, et al. Extremely acute exacerbation of interstitial pneumonia after interferonalpha treatment for metastatic renal cell carcinoma. Int J Clin Oncol. 2009;14:171–3.PubMed
143.
Olivieri D. Desquamative interstitial pneumonitis (DIP) occurring during treatment with pegylated interferon and ribavirin. Respir Med CME. 2009;2:77–9.
144.
Kang EJ, Kim DK, Jeon SR, et al. Interstitial pneumonitis in a patient with chronic hepatitis C and chronic renal failure on interferon therapy. Korean J Gastroenterol. 2011;58:47–52.PubMed
145.
Foster GR, Zeuzem S, Pianko S, et al. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. J Viral Hepat. 2013;20:e115–23.PubMed
146.
Yamamoto S, Tomita Y, Hoshida Y, et al. Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma. J Gastroenterol. 2004;39:793–7.PubMed
147.
Tokita H, Fukui H, Tanaka A, et al. Circulating KL-6 level at baseline is a predictive indicator for the occurrence of interstitial pneumonia during interferon treatment for chronic hepatitis C. Hepat Res. 2003;26:91–7.
148.
Abi-Nassif S, Mark EJ, Fogel RB, et al. Pegylated interferon and ribavirin-induced pneumonitis with ARDS. Chest. 2003;124:406–10.PubMed
149.
Kalambokis G, Stefanou D, Arkoumani E, et al. Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia. Eur J Haematol. 2004;73:67–70.PubMed
150.
Legroux-Crespel E, Lafaye S, Mahé E, et al. Seizures during interferon alpha therapy: three cases in dermatology [Article in French]. Ann Dermatol Venereol. 2003;130:202–4.PubMed
151.
Tan EK, Chan LL, Lo YL. “Myorhythmia” slow facial tremor from chronic interferon alpha-2a usage. Neurology. 2003;61:1302–3.PubMed
152.
Jabbari H, Fakharzadeh E, Merat S, et al. Bell’s palsy associated with chronic HCV infection before and during peginterferon alfa and ribavirin therapy. Arch Iran Med. 2011;14:204–5.PubMed
153.
Kataoka I, Shinagawa K, Shiro Y, et al. Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia. Am J Hematol. 2002;70:149–53.PubMed
154.
Matsuo T, Takabatake R. Multiple sclerosis-like disease secondary to alpha interferon. Ocul Immunol Inflamm. 2002;10:299–304.PubMed
155.
LaRochelle JS, Karp BI. Restless legs syndrome due to interferon-alpha. Mov Disord. 2004;19:730–1.PubMed
156.
Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve. 2002;25:909–13.PubMed
157.
Hwang I, Calvit TB, Cash BD, et al. Bell’s palsy: a rare complication of interferon therapy for hepatitis C. Dig Dis Sci. 2004;49:619–20.PubMed
158.
Hoare M, Woodall T, Alexander GJ. Bell’s palsy associated with IFN-alpha and ribavirin therapy for hepatitis C virus infection. J Interferon Cytokine Res. 2005;25:174–6.PubMed
159.
Perlemuter G, Bodaghi B, Le Hoang P, et al. Visual loss during interferon-alpha therapy in hepatitis C virus infection. J Hepatol. 2002;37:701–2.PubMed
160.
Gupta R, Singh S, Tang R, et al. Anterior ischemic optic neuropathy caused by interferon alpha therapy. Am J Med. 2002;112:683–4.PubMed
161.
Vial T, Descotes J, Braun F, et al. Drugs that act on the immune system: cytokines and monoclonal antibodies. In: Aronson JK, editor. Side effects of drugs annual 28. Amsterdam: Elsevier; 2005. p. 418–9.
162.
Monzani F, Caraccio N, Dardano A, et al. Thyroid autoimmunity and disfunction associated with type I interferon therapy. Clin Exp Med. 2004;3:199–210.PubMed
163.
Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003;13:547–51.PubMed
164.
Tran HA, Reeves GEM, Jones TL. The natural history of interferon-a2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection. Q J Med. 2009;102:117–22.
165.
Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002;36:1273–9.PubMed
166.
Herishanu Y, Trestman S, Kirgner I, et al. Autoimmune thrombocytopenia in chronic myeloid leukemia treated with interferon-alpha: differential diagnosis and possible pathogenesis. Leuk Lymphoma. 2003;44:2103–8.PubMed
167.
Fujii H, Kitada T, Yamada T, et al. Life-threatening severe immune thrombocytopenia during alpha-interferon therapy for chronic hepatitis C. Hepatogastroenterology. 2003;50:841–2.PubMed
168.
Arimura K, Arima N, Ohtsubo H, et al. Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia. Acta Haematol. 2004;112:217–8.PubMed
169.
Andres E, Loukili NH, Ben Abdelghani M, et al. Pernicious anemia associated with interferon-alpha therapy and chronic hepatitis C infection. J Clin Gastroenterol. 2004;38:382.PubMed
170.
Alabdulaaly A, Rifkind J, Solow H, et al. Rescue of interferon induced bone marrow aplasia in a patient with chronic myeloid leukemia by allogeneic bone marrow transplant. Leuk Lymphoma. 2004;45:175–7.PubMed
171.
Chang CS, Yan SL, Lin HY, et al. Pure red cell aplasia caused by pegylated interferon-a-2a plus ribavirin in the treatment of chronic hepatitis C. World J Gastroenterol. 2011;17:2155–8.PubMedPubMedCentral
172.
Zuber J, Martinez F, Droz D, et al. Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Med (Baltimore). 2002;81:321–31.
173.
Nishimura S, Miura H, Yamada H, et al. Acute onset of nephrotic syndrome during interferon-alpha retreatment for chronic active hepatitis C. J Gastroenterol. 2002;37:854–8.PubMed
174.
Ohashi N, Yonemura K, Sugiura T, et al. Withdrawal of interferon-alpha results in prompt resolution of thrombocytopenia and hemolysis but not renal failure in hemolytic uremic syndrome caused by interferon-alpha. Am J Kidney Dis. 2003;41:E10.PubMed
175.
Fisher ME, Rossini M, Simmons E, et al. A woman with chronic hepatitis C infection and nephrotic syndrome who developed multiple renal lesions after interferon alfa therapy. Am J Kidney Dis. 2004;44:567–73.PubMed
176.
Gordon A, Menahem S, Mitchell J, et al. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy. Nephrol Dial Transplant. 2004;19:2155.PubMed
177.
Stadler R, Mayer-da-Silva A, Bratzke B, et al. Interferons in dermatology. J Am Acad Dermatol. 1989;20:650–6.PubMed
178.
Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol. 1995;33:393–410.PubMed
179.
Seckin D, Durusoy C, Sahin S. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol. 2004;21:577–9.PubMed
180.
Grossmann S, Teixeira R, de Aguiar MCF, et al. Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Eur J Gastroenterol Hepatol. 2008;20:702–6.
181.
Sato M, Sueki H, Iijima M. Repeated episodes of fixed eruption 3 months after discontinuing pegylated interferon-alpha-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Clin Exp Dermatol. 2009;34:e814–7.PubMed
182.
Benito-León J, Borbujo J, Cortés L. Cutaneous mucinoses complicating interferon beta-1b therapy. Eur Neurol. 2002;47:123–4.PubMed
183.
Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359:1453–60.PubMed
184.
Hartung HP, Munschauer F III, Schellekens H. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol. 2005;12:588–601.PubMed
185.
Bahri DM, Khiari H, Essouri A, et al. Systemic lupus erythematosus induced by interferon beta1 therapy in a patient with multiple sclerosis. Fundam Clin Pharmacol. 2012;26:210–1.PubMed
186.
Sladkova V, Mares J, Lubenova B, et al. Drug-induced systemic lupus erythematosus in interferon beta-1b therapy. Neuro Endocrinol Lett. 2011;32:4–6.PubMed
187.
Szilasiová J, Gdovinová Z, Jautová J, et al. Cutaneous vasculitis associated with interferon [beta]-1b treatment for multiple sclerosis. Clin Neuropharmacol. 2009;32:301–3.PubMed
188.
Kreisler A, de Seze J, Stojkovic T, et al. Multiple sclerosis, interferon beta and clinical thyroid dysfunction. Acta Neurol Scand. 2003;107:154–7.PubMed
189.
Polman CH, Jansen PH, Jansen C, et al. A rare, treatable cause of relapsing encephalopathy in an MS patient on interferon beta therapy. Neurology. 2003;61:719.PubMed
190.
Guijarro C, Benito-León J, Bermejo-Pareja F. Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis. Neurol Sci. 2011;32:309–11.PubMed
191.
Rosa DJ, de Matias FA, Cedrim SD, et al. Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis. An Bras Dermatol. 2011;86:336–8.PubMed
192.
Nathan CF, Murray HW, Wiebe ME, et al. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983;158:670–89.PubMed
193.
Sidman CL, Marshall JD, Shultz LD, et al. Gammainterferon is one of several direct B cell-maturing lymphokines. Nature. 1984;309:801–3.PubMed
194.
Kurzrock R, Quesada JR, Talpaz M, et al. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol. 1986;4:1101–9.PubMed
195.
Kahan A, Amor B, Menkes CJ, et al. Recombinant interferon-gamma in the treatment of systemic sclerosis. Am J Med. 1989;87:273–7.PubMed
196.
Honoré I, Nunes H, Groussard O, et al. Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis. Am J Respir Crit Care Med. 2003;167:953–7.PubMed
197.
Raghu G, Brown KK, Bradford WZ, et al. Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125–33.PubMed
198.
Carvalho CR, Kairalla RA, Schettino GP. Acute respiratory failure after interferon-gamma therapy in IPF. Am J Respir Crit Care Med. 2004;169:543–4.PubMed
199.
Vlachoyiannopoulos PG, Tsifetaki N, Dimitriou I, et al. Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis. Ann Rheum Dis. 1996;55:761–8.PubMedPubMedCentral
200.
Yamamoto N, Nishigaki K, Ban Y, et al. Coronary vasospasm after interferon administration. Br J Urol. 1998;81:916–7.PubMed
201.
Ault BH, Stapleton FB, Gaber L, et al. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med. 1988;319:1397–400.PubMed
202.
Nair S, Ernstoff MS, Bahnson RR, et al. Interferon-induced reversible acute renal failure with nephrotic syndrome. Urology. 1992;39:169–72.PubMed
203.
Horn TD, Altomonte V, Vogelsang G, et al. Erythroderma after autologous bone marrow transplantation modified by administration of cyclosporine and interferon gamma for breast cancer. J Am Acad Dermatol. 1996;34:413–7.PubMed
204.
Metcalf D. The colony-stimulating factors and cancer. Cancer Immunol Res. 2013;1:351–6.PubMed
205.
Takatsuka H, Takemoto Y, Mori A, et al. Common features in the onset of ARDS after administration of granulocyte colony-stimulating factor. Chest. 2002;121:1716–20.PubMed
206.
Gertz MA, Lacy MQ, Bjornsson J, et al. Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity. J Hematother Stem Cell Res. 2000;9:635–43.PubMed
207.
Couderc LJ, Stelianides S, Frachon I, et al. Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases. Respir Med. 1999;93:65–8.PubMed
208.
Hast R, Hellström-Lindberg E, Ohm L, et al. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia. 2003;17:1827–33.PubMed
209.
Darie C, Boutalba S, Fichter P, et al. Aortite après injections deG-CSF. Rev Med Interne. 2004;25:225–9 (Article in French).PubMed
210.
Deeren DH, Zachee P, Malbrain ML. Granulocyte colony-stimulating factor-induced capillary leak syndrome confirmed by extravascular lung water measurements. Ann Hematol. 2005;84(2):89–94.PubMed
211.
Wang S, Degar BA, Zieske A, et al. Hemophagocytosis exacerbated byG-CSF/GM-CSF treatment in a patient with myelodysplasia. Am J Hematol. 2004;77:391–6.PubMed
212.
Kovacic JC, Macdonald P, Freund J, et al. Profound thrombocytopenia related to G-CSF. Am J Hematol. 2007;82:229–30.PubMed
213.
Nuamah NM, Goker H, Kilic YA, et al. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. Haematologica. 2006;91(5 Suppl):08.
214.
Dagdas S, Ozet G, Alanoglu G, et al. Unusual extramedullary hematopoiesis in a patient receiving granulocyte colony-stimulating factor. Acta Haematol. 2006;116:198–202.PubMed
215.
Socie G, Mary JY, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2007;109:2794–6.PubMed
216.
Gruschkus SK, Lairson D, Dunn JK, et al. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma. Cancer. 2010;116:5279–89.PubMed
217.
Freedman MH, Alter BP. Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias. Semin Hematol. 2002;39:128–33.PubMed
218.
Donadieu J, Leblanc T, Bader Meunier B, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica. 2005;90:45–53.PubMed
219.
Keung YK, Suwanvecho S, Cobos E. Anaphylactoid reaction to granulocyte colony-stimulating factor used in mobilization of peripheral blood stem cell. Bone Marrow Transplant. 1999;23:200–1.PubMed
220.
Fitzhugh CD, Hsieh MM, Bolan CD, et al. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy. 2009;11:464–71.PubMedPubMedCentral
221.
Kumar G, Bernstein JM, Waibel JS, et al. Sweet’s syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment. Am J Hematol. 2004;76:283–5.PubMed
222.
Thompson MA, Dyson SW, Faderl S. Sweet’s syndrome in chronic lymphocytic leukemia associated with neutropenic fever and granulocyte colony stimulation factor. Am J Hematol. 2006;81:703–5.PubMed
223.
Oiso N, Watanabe K, Kawada A. Granulocyte colony-stimulating factor-induced Sweet syndrome in a healthy donor. Br J Haematol. 2006;135:148.PubMed
224.
Feliu J, Díaz R, Contreras F, et al. Worsening psoriasis after treatment with G-CSF in a patient with small-cell lung cancer. J Natl Cancer Inst. 1997;89:1315–6.PubMed
225.
Kavanaugh A. Flare of psoriasis and psoriatic arthritis following treatment with granulocyte colony-stimulating factor. Am J Med. 1996;101:567–8.PubMed
226.
Lenczowski JM1, Cassarino DS, Jain A, et al. Disseminated vascular papules in an immunodeficient patient being treated with granulocyte colony-stimulating factor. J Am Acad Dermatol. 2003;49:105–8.
227.
Alvarez-Ruiz S, Penas PF, Fernandez-Herrera J, et al. Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF. J Eur Acad Dermatol Venereol. 2004;18:310–3.PubMed
228.
Kurokawa I, Umehara M, Iwai T, et al. Exacerbation of palmoplantar pustulosis by granulocyte colony-stimulating factor. Int J Dermatol. 2005;44:529–30.PubMed
229.
Mori T, Sato N, Watanabe R, et al. Erythema exudativum multiforme induced by granulocyte colony-stimulating factor in an allogeneic peripheral blood stem cell donor. Bone Marrow Transplant. 2000;26:239–40.PubMed
230.
Prendiville J, Thiessen P, Mallory SB. Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy. Pediatr Dermatol. 2001;18:417–21.PubMed
231.
Du X, Williams DA. Interleukin-11: Review of molecular, cell biology, and clinical use. Blood. 1997;89:3897–9.PubMed
232.
Smith JW. Tolerability and side-effect profile of rhIL-11. Oncology. 2000;14(9 Suppl 8):41–7.PubMed
233.
Cairo MS, Davenport V, Bessmertny O, et al. PhaseI/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br J Haematol. 2005;128:49–58.PubMed
234.
Hart CE, Forstrom JD, Kelly RA, et al. Two classes of PGDF receptors recognize different isoforms of PGDF. Science. 1988;240:1529–31.PubMed
235.
Seifert RA, Hart CE, Phillips PE, et al. Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. J Biol Chem. 1989;264:8771–8.PubMed
236.
Pierce GF, Mustoe TA, Altrock BW, et al. Role of platelet-derived growth factor in wound healing. J Cell Biochem. 1991;45:319–26.PubMed
237.
Pierce GF, Tarpley JE, Allman RM, et al. Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB. Am J Pathol. 1994;145:1399–410.PubMedPubMedCentral
238.
Robson MC, Phillips LG, Thomason A, et al. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet. 1992;339:23–5.PubMed
239.
240.
Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Eng J Med. 1987;316:889–97.
241.
Thompson JA, Lee DJ, Lindgren CG, et al. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res. 1989;49:235–40.PubMed
242.
Lee RE, Lotze MT, Scibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1989;7:7–20.PubMed
243.
Osanto S, Cluitmans FHM, Franks CR, et al. Myocardial injury after interleukin-2 therapy. Lancet. 1988;2:48–9.PubMed
244.
Thavendiranathan P, Verhaert D, Kendra KL, et al. Fulminant myocarditis owing to high-dose interleukin-2 therapy for metastatic melanoma. Br J Radiol. 2011;84:e99–102.PubMed
245.
Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology. 2002;16(11 Suppl 13):11–20.PubMed
246.
Nora R, Abrams JS, Tait NS, et al. Myocardial toxic effects during recombinant interleukin-2 therapy. J Natl Cancer Inst. 1989;81:59–63.PubMed
247.
Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002;20:2045–52.PubMed
248.
MacFarlane PM, Yang JC, Guleria AJ, et al. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. Cancer. 1995;75:1030–7.PubMed
249.
Krouse RS, Royal RE, Heywood G, et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother. 1996;18:272–8.
250.
Cormier JN, Hurst R, Vasselli J, et al. A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2. J Immunother. 1997;20:292–300.PubMed
251.
Heimann DM, Schwartzentruber DJ. Gastrointestinal perforations associated with interleukin- 2 administration. J Immunother. 2004;27:254–8.PubMed
252.
Pizzi C, Caraglia M, Cianciulli M, et al. Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI). Anticancer Res. 2002;22:727–32.PubMed
253.
Tranvan A, Pezen DS, Medenica M, et al. Interleukin-2 associated linear IgA bullous dermatosis. J Am Acad Dermatol. 1996;35:865–7.PubMed
254.
Segura Huerta AA, Tordera P, Cercós AC, et al. Toxic epidermal necrolysis associated with interleukin-2. Ann Pharmacother. 2002;36:1171–4.PubMed
255.
O’Reilly F, Feldman E, Yang J, et al. Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2. J Am Acad Dermatol. 2003;48:602–4.PubMed
256.
Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1006–12.PubMedPubMedCentral
257.
Turesson C, Riesbeck K. Septicemia with Staphylococcus aureus, beta-hemolytic streptococci group B and G, and Escherichia coli in a patient with rheumatoid arthritis treated with a recombinant human interleukin 1 receptor antagonist (anakinra). J Rheumatol. 2004;31:1876.PubMed
258.
Settas LD, Tsimirikas G, Vosvotekas G, et al. Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). J Clin Rheumatol. 2007;13:219–20.PubMed
259.
Swart JF, Barug D, Mohlmann M, et al. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Ther. 2010;10:1743–52.PubMed
260.
Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302–8.PubMed
261.
Carter JD, Valeriano J, Vasey FB. Crohn disease worsened by anakinra administration. J Clin Rheumatol. 2003;9:276–7.PubMed
262.
Desai D, Goldbach-Mansky R, Milner JD, et al. Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs. Ann Pharmacother. 2009;43:967–72.PubMedPubMedCentral
263.
Livory M, Wechsler J, Revuz J, et al. Cellulite de Wells et dermohypodermite bactérienne nécrosante induites par l’anakinra [Wells’ cellulitis and bacterial necrotizing cellulitis induced by anakinra.]. Ann Dermatol Venereol. 2008;135:839–42.PubMed
264.
Regula CG, Hennessy J, Clarke LE, et al. Interstitial granulomatous drug reaction to anakinra. J Am Acad Dermatol. 2008;59(2 Suppl 1):S25–7.PubMed
265.
266.
Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with endstage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111:992–1000.PubMed
267.
Nowicki M. Erythropoietin and hypertension. J Hum Hypertens. 1995;9:81–8.PubMed
268.
Manolis AS, Tzeis S, Triantafyllou K, et al. Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects. Curr Drug Targets—Cardiovasc Haematol Disorders. 2005;5:355–75.
269.
Sowade B, Sowade O, Mocks J, et al. The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med. 1998;1:303–14.PubMed
270.
Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40:2201–16.PubMed
271.
272.
Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351:1403–8.PubMed
273.
Weber G, Gross J, Kromminga A, et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol. 2002;13:2381–3.PubMed
274.
Garcia JE, Senent C, Pascual C, et al. Anaphylactic reaction to recombinant human erythropoietin. Nephron. 1993;65:636–7.PubMed
275.
Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part II (BMP delivery). J Tissue Eng Regen Med. 2008;2:81–96.PubMed
276.
Bragdon B, Moseychuk O, Saldanha S, et al. Bone morphogenetic proteins: a critical review. Cell Signal. 2011;23:609–20.PubMed
277.
Ong KL, Villarrarga ML, Lau E, et al. Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila, Pa). 2010;35:1794–800.
278.
Cahill KS, Chi JH, Day A, et al. Prevalence, complications and hospital charges associated with the use of bone-morphogenetic proteins in spinal fusion procedures. JAMA. 2009;302:58–66.PubMed
279.
Mindea SA, Shih P, Song JK. Recombinant human bone morphogenetic protein-2-induced radiculitis in elective minimally invasive transforaminal lumbar interbody fusions: a series review. Spine. 2009;34:1480–4.PubMed
280.
Comer GC, Smith MW, Hurwitz EL, et al. Retrograde ejaculation after anterior lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a 10-year cohort controlled study. Spine J. 2012;12:881–90.PubMed
281.
Mroz TE, Wang JC, Hashimoto R, et al. Complications related to osteobiologics use in spine surgery: a systematic review. Spine. 2010;35(Suppl 9):S86–104.PubMed
282.
283.
Koehler SM, Latridis JC, Hecht A, et al. Does BMP-2 really cause cancer? A systematic review of the literature—NASS meeting 2012. Spine J. 2012;12:S143–4.
284.
Simmonds MC, Brown JV, Heirs MK, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual participant data. Ann Intern Med. 2013;158:177–9.
285.
Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions: a prospective, randomized clinical trial comparing rhOP-1 with fresh bone autograft. J Bone Joint Surg Am. 2001;83-A(Suppl 1,Pt 2):S151–8.PubMed
286.
Leach J, Bittar RG. BMP-7 (OP-1®) safety in anterior cervical fusion surgery. J Clin Neurosci. 2009;16:1417–20.PubMed
287.
288.
Kelesidis T, Kelesidis I, Chou S, et al. Narrative review: the role of leptin in human physiology: EMERGING clinical applications. Ann Intern Med. 2010;152:93–100.PubMedPubMedCentral
289.
Wong SL, Depaoli AM, Lee JH, et al. Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates. J Clin Endocrinol Metabol. 2004;89:2672–7.
290.
Javor ED, Moran SA, Ryan J, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metabol. 2004;89:3199–207.
291.
Beltrand J, Lahlou N, Charpentier T, et al. Resistance to leptin-replacement therapy in Berardinelli- Seip congenital lipodystrophy: an immunological origin. Eur J Endocrinol. 2010;162:1083–91.PubMed
292.
Housa D, Housová J, Vernerová Z, et al. Adipocytokines and Cancer. Physiol Res. 2006;55:233–44.PubMed
293.
294.
Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–18.PubMed
Metadata
Title
Side Effects of Cytokines Approved for Therapy
Author
Brian A. Baldo
Publication date
01-11-2014
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 11/2014
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-014-0226-z

Other articles of this Issue 11/2014

Drug Safety 11/2014 Go to the issue

Original Research Article

Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)

Original Research Article

Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database

Review Article

Pharmacotherapy of Type 2 Diabetes Mellitus: An Update on Drug–Drug Interactions

Erratum

Erratum to: Adverse Gastrointestinal Events with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Nested Case–Control Study

Current Opinion

Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications

Commentary

Converting to a Common Data Model: What is Lost in Translation?